Cutaneous syncytial myoepithelioma (CSM) is a rare type of cutaneous neoplasm that typically presents as a solitary and well-circumscribed nodule on the skin. It predominantly occurs on the upper and lower extremities of adult patients. Immunohistochemically, CSM is characterized by the co-expression of smooth muscle and epithelial markers. Fluorescence in situ hybridization (FISH) targeting the EWSR1 gene rearrangement is an important diagnostic tool for CSM. In our case report, we found the focal positivity for CD34, which has never been previously observed; this was mostly confined to a central area of the neoplasm.

Introduction: Actinic keratosis (AK) is a common precancerous skin lesion that arises on chronically UV-exposed skin and can progress to keratinocyte carcinoma. Objective: The aim of this study is to compare efficacy, safety, local skin reaction, time to wound closure, and patient preference of imiquimod (IMQ) 3.75% vs 5-fluorouracil (5-FU) 4% cream treatment for AKs. Methods: Two symmetrical contralateral areas of approximately 25 cm2 harboring a similar (≥5) number of AKs were selected and randomly assigned to IMQ 3.75% or 5- FU 4% cream treatment. The total number of AKs for each patient, was evaluated at baseline (T0) and 90 days after the end of treatments (T1). Local skin reaction (LSR) score was registered the day after the end of both treatments. Complete remission rate of lesions, cosmetic outcome, and patient preference of treatment were assessed after 90 days (T1). Results: The mean variation (ΔT0-T1) of AKs was not significantly different in patients treated with IMQ 3.75% and 5-FU 4% (p=0.35). The mean LSR was not significantly different for patients treated with IMQ 3.75% and 5-FU 4% (p=0.63). No difference in cosmetic outcome was observed in the 2 groups. Patient preference was equally distributed between the treatments. The mean time to wound closure after the end of the treatment was similar after IMQ 3.75% as compared to 5-FU 4% (p=0.83). Conclusions: This study reports a non-superiority of efficacy, tolerability, wound-healing time, and cosmetic outcome of topical IMQ 3.75% treatment compared to topical 5-FU 4% treatment in AK management.

Introduction: Actinic keratosis (AK) is a precancerous skin lesion that can progress to keratinocyte carcinoma. Objective: The objective of the study was to evaluate the efficacy of a dermocosmetic (DC) formulation containing prebiotic active ingredients (Aqua Posae Filiformis, a complex made of ferments, sugars, plant extracts, panthenol, madecassoside, and zinc) on healing time and local skin reactions (LSR) following cryotherapy of AKs and to compare the application of DC aand boric acid 3% solution soaks (BA) vs. BA alone. Methods: Seventy-five adult patients presenting with a maximum of 5 isolated AKS on the face and/or scalp and who underwent cryotherapy (T0) were enrolled. Post-treatment, patients initiated the application of BA only or BA followed by DC once daily for 30 days (unblinded 1:1 randomization). The evaluation of efficacy in healing time and cosmetic outcomes was assessed 30 days post-treatment (T2); LSR was evaluated 3 days post-treatment (T1). Results: There was a gain of 4.5 days (40%) in healing time in the BA+DC group compared to the BA group, with a median time of 7 days versus 11.5 days (P<0.0005). Additionally, 50% of lesions in complete response had an excellent cosmetic outcome with BA+DC vs. 20% with BA only. The majority of patients treated with BA+DC had mild LSR vs. moderate LSR with BA, with a median value of 2 vs 3, respectively (P<0.0001). Conclusion: The addition of a prebiotic DC significantly reduced healing time, improved cosmetic outcomes, and minimized LSR post-cryotherapy. No adverse events were reported with this treatment.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (dual GIP/GLP-1 agonists) have rapidly changed the management of obesity and type 2 diabetes mellitus. Beyond their effects on weight reduction and glycemic control, these agents exert pleiotropic effects on inflammation, adipose tissue biology, endothelial function and tissue repair, properties of growing relevance to dermatology, where several chronic inflammatory diseases are closely linked to obesity, insulin resistance and systemic low-grade inflammation. Current evidence suggests potential clinical benefit in psoriasis and hidradenitis suppurativa, encouraging signals regarding wound healing and a generally favorable cutaneous safety profile, although cutaneous adverse events, including injection site reactions, hypersensitivity, alopecia and rare autoimmune eruptions, have been increasingly reported. This review summarizes the immunometabolic rationale, current clinical evidence, the dermatologic safety profile and future perspectives of GLP-1RAs and dual GIP/GLP-1 agonists in dermatology. Although available data remain heterogeneous and largely observational outside psoriasis and hidradenitis suppurativa, these therapies may represent a new class of systemic immunometabolic modulators with practical implications for inflammatory, surgical and aesthetic dermatology.